

Figure S1 The flow chart of patient enrollment and exclusion in this study. mUTUC, metastatic upper tract urothelial carcinoma; PD-1, programmed cell death 1.




Figure S2 The CT image of a patient revealed a reduction of lung metastasis (indicated by the red arrow) after a 2-month treatment with tislelizumab in combination with nab-paclitaxel. CT, computed tomography.